Literature DB >> 32423639

Emerging Targets for Cardiovascular Disease Prevention in Diabetes.

Nathan O Stitziel1, Jenny E Kanter2, Karin E Bornfeldt3.   

Abstract

Type 1 and type 2 diabetes mellitus (T1DM and T2DM) increase the risk of atherosclerotic cardiovascular disease (CVD), resulting in acute cardiovascular events, such as heart attack and stroke. Recent clinical trials point toward new treatment and prevention strategies for cardiovascular complications of T2DM. New antidiabetic agents show unexpected cardioprotective benefits. Moreover, genetic and reverse translational strategies have revealed potential novel targets for CVD prevention in diabetes, including inhibition of apolipoprotein C3 (APOC3). Modeling and pharmacology-based approaches to improve insulin action provide additional potential strategies to combat CVD. The development of new strategies for improved diabetes and lipid control fuels hope for future prevention of CVD associated with diabetes.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  angiopoietin-like; apolipoprotein C3; atherosclerosis; diabetes; genetics; insulin

Mesh：

Substances：

Year:  2020        PMID： 32423639      PMCID： PMC7395866          DOI： 10.1016/j.molmed.2020.03.011

Source DB:  PubMed          Journal:  Trends Mol Med        ISSN： 1471-4914            Impact factor:   11.951


  123 in total

1.  Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo.

Authors:  H N Ginsberg; N A Le; I J Goldberg; J C Gibson; A Rubinstein; P Wang-Iverson; R Norum; W V Brown
Journal:  J Clin Invest       Date:  1986-11       Impact factor: 14.808

2.  ApoC-III content of apoB-containing lipoproteins is associated with binding to the vascular proteoglycan biglycan.

Authors:  Katherine Olin-Lewis; Ronald M Krauss; Michael La Belle; Patricia J Blanche; P Hugh R Barrett; Thomas N Wight; Alan Chait
Journal:  J Lipid Res       Date:  2002-11       Impact factor: 5.922

3.  Treatment of diabetic rats with insulin or a synthetic insulin receptor agonist peptide leads to divergent metabolic responses.

Authors:  Henriette Frikke-Schmidt; Thomas Å Pedersen; Christian Fledelius; Grith S Olsen; Stephan D Bouman; Mark Fitch; Marc Hellerstein
Journal:  Diabetes       Date:  2014-10-14       Impact factor: 9.461

4.  Fructose-induced hypertriglyceridemia in rhesus macaques is attenuated with fish oil or ApoC3 RNA interference.

Authors:  Andrew A Butler; Candice A Price; James L Graham; Kimber L Stanhope; Sarah King; Yu-Han Hung; Praveen Sethupathy; So Wong; James Hamilton; Ronald M Krauss; Andrew A Bremer; Peter J Havel
Journal:  J Lipid Res       Date:  2019-02-05       Impact factor: 5.922

5.  Expression of apolipoprotein C-III in McA-RH7777 cells enhances VLDL assembly and secretion under lipid-rich conditions.

Authors:  Meenakshi Sundaram; Shumei Zhong; Maroun Bou Khalil; Philip H Links; Yang Zhao; Jahangir Iqbal; M Mahmood Hussain; Robin J Parks; Yuwei Wang; Zemin Yao
Journal:  J Lipid Res       Date:  2010-01       Impact factor: 5.922

Review 6.  Validating therapeutic targets through human genetics.

Authors:  Robert M Plenge; Edward M Scolnick; David Altshuler
Journal:  Nat Rev Drug Discov       Date:  2013-07-19       Impact factor: 84.694

7.  Chronic kidney disease delays VLDL-apoB-100 particle catabolism: potential role of apolipoprotein C-III.

Authors:  Doris T Chan; Gursharan K Dogra; Ashley B Irish; Esther M Ooi; P Hugh Barrett; Dick C Chan; Gerald F Watts
Journal:  J Lipid Res       Date:  2009-06-21       Impact factor: 5.922

Review 8.  Lipoprotein lipase and lipolysis: central roles in lipoprotein metabolism and atherogenesis.

Authors:  I J Goldberg
Journal:  J Lipid Res       Date:  1996-04       Impact factor: 5.922

9.  Transcriptional regulation of the apoC-III gene by insulin in diabetic mice: correlation with changes in plasma triglyceride levels.

Authors:  M Chen; J L Breslow; W Li; T Leff
Journal:  J Lipid Res       Date:  1994-11       Impact factor: 5.922

Review 10.  Mendelian randomisation in cardiovascular research: an introduction for clinicians.

Authors:  Derrick A Bennett; Michael V Holmes
Journal:  Heart       Date:  2017-06-08       Impact factor: 5.994
View more
  6 in total

Review 1.  Diabetes, Lipids, and CV Risk.

Authors:  Jan Škrha
Journal:  Curr Atheroscler Rep       Date:  2021-01-19       Impact factor: 5.113

2.  Development and validation of risk prediction models for stroke and mortality among patients with type 2 diabetes in northern China.

Authors:  X Shao; H Liu; F Hou; Y Bai; Z Cui; Y Lin; X Jiang; P Bai; Y Wang; Y Zhang; C Lu; H Liu; S Zhou; P Yu
Journal:  J Endocrinol Invest       Date:  2022-08-16       Impact factor: 5.467

3.  Hypercoagulability Impairs Plaque Stability in Diabetes-Induced Atherosclerosis.

Authors:  Saira Ambreen; Sameen Fatima; Ahmed Elwakiel; Rajiv Rana; Kunal Singh; Anubhuti Gupta; Dheerendra Gupta; Hamzah Khawaja; Jayakumar Manoharan; Christian Besler; Ulrich Laufs; Shrey Kohli; Berend Isermann; Khurrum Shahzad
Journal:  Nutrients       Date:  2022-05-10       Impact factor: 6.706

4.  ER-Stress and Senescence Coordinately Promote Endothelial Barrier Dysfunction in Diabetes-Induced Atherosclerosis.

Authors:  Sameen Fatima; Saira Ambreen; Akash Mathew; Ahmed Elwakiel; Anubhuti Gupta; Kunal Singh; Shruthi Krishnan; Rajiv Rana; Hamzah Khawaja; Dheerendra Gupta; Jayakumar Manoharan; Christian Besler; Ulrich Laufs; Shrey Kohli; Berend Isermann; Khurrum Shahzad
Journal:  Nutrients       Date:  2022-07-06       Impact factor: 6.706

Review 5.  New Progress in Early Diagnosis of Atherosclerosis.

Authors:  Heyu Meng; Jianjun Ruan; Zhaohan Yan; Yanqiu Chen; Jinsha Liu; Xiangdong Li; Fanbo Meng
Journal:  Int J Mol Sci       Date:  2022-08-11       Impact factor: 6.208

6.  Triglyceride lowering by omega-3 fatty acids: a mechanism mediated by N-acyl taurines.

Authors:  Karin E Bornfeldt
Journal:  J Clin Invest       Date:  2021-03-15       Impact factor: 14.808
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.